I

InflaRx NV
D

IFRX

0.77000
USD
-0.04
(-4.94%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
52,165,290
أصول ذات صلة
A
AMRN
-0.080
(-0.60%)
13.250 USD
C
CRBP
-0.36000
(-3.92%)
8.83000 USD
M
MTNB
-0.02200
(-2.52%)
0.85000 USD
V
VKTX
-2.510
(-8.78%)
26.070 USD
المزيد
الأخبار المقالات

العنوان: InflaRx NV

القطاع: Healthcare
الصناعة: Biotechnology
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.